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HLHS is caused by the up regulation of HIF1α due to hypoxia caused by a polymorphism in
eNOS.
Tyler Bruinsma, Kevin Curwick, Leah Elman, Jared Grootwassink, Thomas O’Toole
Dr. Katherine Furniss Ph.D
College of Saint Benedict and Saint John’s University, Saint Joseph and Collegeville, MN
Background Information
Hypoplastic left heart syndrome (HLHS) is a rare congenital heart defect occurring in fewer
than 0.5% of live births in the United States (Fruitman, 2000). It is characterized by a critically
underdeveloped left ventricle with accompanying imperfections including septal defects, undersized aorta, and underdeveloped bicuspid and aortic semilunar valves (Mayo Clinic Staff, 2012;
CDC, 2013). HLHS is detectable on ultrasound at the end of the first trimester of pregnancy
allowing for early diagnosis and potential treatment in utero. While a protocol involving three
surgeries exists to treat the condition, there is no cure for HLHS. Even with treatment, many
patients eventually require a heart transplant due to congestive heart failure.
Hypothesis and Rationale
We hypothesize that HLHS is caused by an up-regulation of hypoxia-inducible factor 1α
(HIF1α) caused by prolonged hypoxia in the developing heart. Furthermore, we propose that a
polymorphism in the endothelial nitric oxide synthase gene (eNOS) causes a decrease in basal levels
of nitric oxide (NO), a potent vasodilator, in the blood stream and contributes to hypoxia. HIF1α
expression, brought about by hypoxia and other environmental factors, regulates a number of
transcription factors and genes vital to normal cardiogenesis. These factors combine to form a
perfect storm in the developing heart, leading to the development of HLHS.
When working properly, the eNOS enzyme promotes production and regulation of NO
which dilates blood vessels and allows for proper blood flow throughout the body. eNOS is
expressed in endothelial cells during early stages of cardiogenesis and naturally depletes starting as
early as embryonic stage 14.5 (between days 33-36 of pregnancy) with only small traces remaining
at birth (Bloch et al., 1999). Many researchers have identified that a polymorphism on exon 7 of the
eNOS gene, G894T, leads to a greater risk for congenital heart defects during early cardiogenesis
(van Beynum et al., 2008; Bloch et al., 1999; Feng et al., 2002; Shaw, et al., 2005; Zhou et al.,
2014). The polymorphism corresponds to a down regulation of NO, leading to an inability to control
blood pressure, cardiomyocyte apoptosis, and cell growth in cardiogenesis (Feng et al., 2002).
Specifically, van Beynum et al. (2008) demonstrates a positive relationship between the G894T
polymorphism and structural deformations of the heart. Feng et al. (2002) attributes the identified
structural deformations to the increased and uncontrolled cardiomyocyte apoptosis found as a result
of eNOS deficiency. Another result of the polymorphism is a decrease in available cyclic guanosine
monophosphate (cGMP) (Bloch et al., 1999), which relates to the mechanism of vasodilation by NO
(McQuillan, Leung, Marsden, Kostyk, & Kourembanas, 1994). Due to downregulation of NO,
blood flow becomes restricted during cardiac development and prolonged hypoxia arises as a
detriment to cardiogenesis.
Hypoxia-inducible factor 1α (HIF1α) is a dimer of the heterodimeric transcription factor,
HIF1 (Ziello, Jovin, and Huang, 2007). According to Balligand, Feron, and Dessy, (2009) HIF1α is
activated through various pathways, including hypoxia. HIF1α is hydroxylated in the combined
presence of oxygen and prolyl hydroxylase (PHD), and is then degraded after binding to the von
Hippel Lindau protein (pVHL). This process acts to regulate levels of HIF1α during periods of
normal oxygenation. When confronted with conditions, such as hypoxia, that prevent HIF1α’s
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hydroxylation, HIF1α is able to stabilize and complete the HIF1 complex after migrating to the cell
nucleus. This contributes to increased levels of HIF1α during periods of low oxygenation
(Balligand, Feron, and Dessy, 2009). While low oxygenation has been shown to increase levels of
HIF1α, many other factors such as increased stress, NO levels, and inflammation have also been
shown to increase levels of HIF1α (Gorlach, 2009). Chronic diseases, such as cardiovascular
disease, diabetes, and autoimmune diseases as well as chronic environmental stress all contribute to
higher levels of inflammatory proteins. If an epidemiological connection can be found among
mothers of HLHS patients who have any of these diseases or environmental factors, increased
HIF1α levels may be preliminarily implicated as the cause of HLHS.
Gaber and colleagues (2013) studied left ventricle tissue samples from aborted, second
trimester fetuses who were found to have HLHS and compared them to control samples obtained in
a similar manner. HLHS samples were found to have higher nuclear expression of HIF1α.
Furthermore, the phenomenon was mimicked in vitro using human pluripotent stem cells (hPSC’s).
hPSC’s subjected to a hypoxic state during cardiac differentiation showed elevated HIF1α levels.
The authors of the study indicate that this data points strongly to the assertion that hypoxia can
reprogram the developing heart (Gaber, et al., 2013). This new data aligns with existing evidence
that HIF1α plays an essential role in cardiac development by regulating key genes in ventricular
formation (Compernolle et al., 2003).
According to Krishnan et al, (2008) it has also been determined that HIF1α contributes to
the regulation of NKX2.5, TBX5, and MEF2C. NKX2.5 and MEF2C are expressed very early on in
the heart field of the developing embryo and continue to be expressed into the late stages of
development. They are considered some of the earliest cardiac indicators (George, Colombo,
Tergoff, 2014; Srivastava, Olson, 2000). NKX2.5 is also vital to the development of ventricular
identity in the transition from the anterior-posterior patterning to the left-right patterning in the
developed heart. Region specific knockouts of NKX2.5 exhibit elevated levels of Bmp10 which
leads to hypertrophy of the developing ventricles (Gilbert, 2010). TBX5 is expressed exclusively in
the left ventricle asymmetric to TBX20 in the right ventricle during heart patterning and ventricular
septation. Together these genes are vital for normal ventricular septum formation and normal
ventricular development (Gilbert, 2010).
HIF1α is believed to regulate TBX5 and NKX2.5 by binding to Hypoxia Response Elements
(HREs) contained within the promoters of the respective gene on the DNA. By binding to the
promoter, the transcription of the gene is down regulated. (Krishnan et al., 2008). Experiments have
shown that irregularly low doses of HIF1α result in the up-regulation of NKX2.5, TBX5, and
MEF2C (Bohuslavova, et. al. 2013). Therefore, high doses of HIF1α likely result in the down
regulation of these specific factors. The evidence-based roles of these downstream factors further
implicate our proposed pathway connecting hypoxia and HIF1α to the development of HLHS.
The full phenotypic scope of irregular expression of HIF1α and its regulation of downstream
proteins and transcription factors is currently not well understood. There is, however, phenotypic
evidence that, in tandem with our proposed pathway, points to the potential role of hypoxia and
HIF1α in HLHS. Research has found that hearts afflicted with HLHS exhibit reduced levels of
connexin 43 in intercalated discs (Mahtab, et. al, 2012), and that connexin 43 may be reduced under
the same hypoxic conditions that promote HIF1α expression (Xianghong, et. al, 2013).
Additionally, z-discs interact with titin and α-actinin to function properly, and both titin and αactinin have been exhibited in decreased levels when HIF1α levels are reduced (Krishnan).
Therefore, it is possible that the inverse may be true, where increased levels of HIF1α lead to an
overexpression of titan and α-actinin. Alpha-actinin is highly important in heart sarcomere function,
and unusual expression may be linked to HLHS (Chiu, et. al, 2010; Wang, 2013). The importance
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of these findings is not necessarily about how they function to create HLHS (as much information
in that area has yet to be discovered). Rather, their importance lies in their ability to link HIF1α to
the disease.
Significance and Innovation
A preliminary epidemiological study could provide a level of validity for our hypothesis. If
mothers of HLHS patients tend to have inflammatory protein-causing diseases, our hypothesis
connecting HIF1α to HLHS would be preliminarily supported. Additionally, we propose a series of
simple laboratory tests. First, we propose the sequencing and analysis of HLHS patient samples for
the eNOS polymorphism G894T. Next, we propose a simple ELISA assay to test for abnormal
levels of HIF1α in cardiomyocytes derived from induced pluripotent stem cells (iPSCs) from HLHS
patients. If a relevant correlation between the presence of a G894T and elevated levels of HIF1α
exists, our pathway would be supported. In the future, it would be possible to perform both of these
tests in utero, allowing for early diagnosis and potential prophylaxis. Tests may also be performed
on the parents prior to pregnancy to screen for a predisposition to the G894T polymorphism or
elevated HIF1α.
In the event that early screenings using our proposed tests indicate a predisposition to
HLHS, we hypothesize that it is possible to prevent the development of HLHS by attempting to
treat the abnormal phenotype created by this polymorphism. This may be possible through the use
of ACE inhibitors, statins or vasodilators, which have been proven to activate eNOS (Balligand,
Feron, & Dessy, 2009). This would not only remedy the vasoconstriction caused by a lack of NO
due to abnormal levels of eNOS, but it would also provide one mechanism to avoid the
accumulation of HIF1α, preventing the abnormal downstream regulation of NKX2.5, TBX5, and
MEF2C.
Our hypothesis is significant because if supported it relies on a simple genetic test to
determine if potential parents are at risk for passing on the polymorphisms to their offspring. If
parents choose to have a child despite the risk there is the potential for treatment in utero that would
remove the environmental conditions (hypoxia) that lead to the development of HLHS. The
combination of genetic screening and in utero treatment could lead to the cure for HLHS ensuring
no more children are born with this heart defect. Ultimately our proposed pathway is novel because
it connects a polymorphism in eNOS to hypoxia, elevated HIF1α, various cardiac progenitors, and
finally the development of HLHS.
Summary
The G894T polymorphism in eNOS during early stages of embryonic cardiogenesis results
in a reduction of basal NO production, which results in vasoconstriction and prevention of HIF1α
degradation. As a result, prolonged hypoxia in the developing heart brings about an accumulation of
HIF1α. When combined with environmental factors such as inflammation and depleted levels of
NO, the uncontrolled levels of HIF1α down regulate TBX5, NKX2.5, and MEF2C; genes
responsible for development of the left ventricle. Compounded with data demonstrating that
degradation of eNOS results in uncontrolled cardiomyocyte apoptosis, the greater expression of
HIF1α results in an underdeveloped left ventricle corresponding to HLHS. Simple parental PCR
testing for the G894T polymorphism in eNOS and ELISA assay for observing abnormal levels of
HIF1α in iPSCs can result in an accurate diagnosis through our proposed mechanism of HLHS. A
proposed treatment regimen calls for ACE inhibitors or statins to promote eNOS activation, leading
to greater prevalence of NO, which eliminates one factor contributing to HIF1α abundance.
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